Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.7K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.1K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.3K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.

British journal of haematology·2026
Same author

Exploration of the radiation dose-toxicity relationship for multiple ophthalmological organs at risk for pediatric patients assessed in long-term head and neck rhabdomyosarcoma survivors.

Clinical and translational radiation oncology·2026
Same author

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial.

Journal of the National Cancer Institute·2026
Same author

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
Same author

2D or not 2D? For Total Body Irradiation, That Is the Question.

International journal of radiation oncology, biology, physics·2026
Same author

Highly conformal whole abdominopelvic radiotherapy: Consensus delineation guidelines from EpSSG and QUARTET.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Related Experiment Video

Updated: Nov 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.4K

Non-rhabdomyosarcoma soft-tissue sarcoma.

Sarah A Milgrom1, Lynn Million2, Henry Mandeville3

  • 1Department of Radiation Oncology, University of Colorado, Denver, Colorado.

Pediatric Blood & Cancer
|April 5, 2021
PubMed
Summary
This summary is machine-generated.

Non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) are rare childhood cancers. Current treatment focuses on surgery, radiation, and chemotherapy, with ongoing research aiming for risk-based approaches to improve outcomes and reduce toxicity.

Keywords:
COGNRSTSSIOPchemotherapynon-rhabdomyosarcoma soft-tissue sarcomapazopanibradiation therapysarcomasurgery

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.9K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.6K

Related Experiment Videos

Last Updated: Nov 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.9K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.6K

Area of Science:

  • Pediatric Oncology
  • Surgical Oncology
  • Radiation Oncology

Background:

  • Non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) represent 4% of pediatric malignancies.
  • These tumors encompass diverse histologic subtypes with variable prognoses.
  • Key adverse prognostic factors include high grade, large size, metastasis, and unresectability.

Purpose of the Study:

  • To review the current management strategies for pediatric NRSTS.
  • To outline the roles of surgery, radiation therapy (RT), and chemotherapy in NRSTS treatment.
  • To highlight ongoing research and future directions in NRSTS care.

Main Methods:

  • Review of current treatment paradigms for NRSTS.
  • Summary of established prognostic factors influencing treatment decisions.
  • Discussion of ongoing clinical trials and risk-based treatment approaches.

Main Results:

  • Complete surgical resection is paramount for optimal oncologic outcomes.
  • RT and chemotherapy are utilized based on tumor characteristics like resectability, grade, size, and stage.
  • Risk-based strategies are being developed to balance treatment efficacy and toxicity.

Conclusions:

  • Multimodal therapy, including surgery, RT, and chemotherapy, is essential for managing pediatric NRSTS.
  • Risk stratification is crucial for tailoring treatment and minimizing long-term side effects.
  • Continued research is vital for advancing therapeutic options and improving survival rates for NRSTS patients.